Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in gout.

Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25101

Enrollment

Registered

2007-02-12

Start date

2005-06-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout, hyperuricemia

Interventions

stage 1: allopurinol 1dd 300mg (8 weeks). stage 2: A. benzbromarone 1dd 200mg (8 weeks)

B. probenecide 2dd 1000mg (8 weeks).

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >18 year; 2. Diagnosis gout based on crystal evidence or ARA criteria; 3. Eestimated creatinine clearance >50 ml/min; 4. Baseline values measured: serum urate, urinary urate excretion, serum creatinine.

Exclusion criteria

Exclusion criteria: 1. Contra-indication for allopurinol, benzbromaron or probenecid; 2. Prior treatment with allopurinol, benzbromaron or probenecid.

Design outcomes

Primary

Measure	Time frame
Success rate on study medication consisting of patient tolerability and attainment of target level serum urate <0.30 mmol/l after 8 weeks treatment.	—

Secondary

Measure	Time frame
1. Serum urate lowering effect (% decrease) of the antihyperuricemic agent; 2. tolerability of the antihyperuricemic agent (adverse drug reactions).	—

Contacts

Public ContactM.K. Reinders

Medical Centre Leeuwarden Department of Clinical Pharmacy and Pharmacology Postbox 888

m.reinders@znb.nl0031 58 2866610

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)